CME Symposium - Evolving Management of Opioid-Induced Constipation In Patients with Chronic Pain

ORLANDO, Fla. - March 3, 2014 - PRLog -- Click to Register Online

Evolving Management of Opioid-Induced Constipation in Patients with Chronic Pain

Chair
Jeffrey A. Gudin, MD
Director, Pain Management and Pallative Care
Englewood Hospital and Medical Center
Englewood, New Jesey

Faculty
Anthony J. Lembo, MD
Associate Professor of Medicine
Harvard Medical School
Boston, Massachussetts

Michael J. Brennan, MD
Associate Director, Chronic Pain and Recovery Program
Silver Hill Hospital
New Canaan, Connecticut
Senior Attending Physician
Bridgeport Hospital
Bridgeport, Connecticut

Click To Register Online

Chronic pain constitutes a major public health problem in the United States. As a result, the use of opioid analgesics has increased exponentially. For the patient who has been prescribed opioid analgesics, constipation is just one of the many side effects with which the patient is burdened. Yet, unlike sedation or nausea, opioid-induced constipation (OIC) does not subside. This not only complicates therapy, with the patient sometimes becoming non-adherent to the medication for the sole purpose of having a bowel movement but OIC can become a different type of pain the patient must endure. Therefore, assessment and treatment to prevent or ameliorate OIC is an essential component of pain management. Current management for OIC is nonspecific and often ineffective. However, medications are now emerging that target the underlying cause of OIC by acting specifically and locally within the GI tract.

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Voxmedia LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP.

Pre-registration is for planning purposes only.
For additional CME activities and online cme courses visit CMEPlanet